ReviewFrontiers in cardiovascular medicine2021
Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- A systematic review and dose-response meta-analysis of red blood cell distribution width to albumin ratio as mortality predictor in cardiovascular disease.Scientific reports · 2025Pooled it
- Systematic review and meta-analysis of cardiovascular associated biomarkers in adults with asymptomatic autoimmune diseases.Frontiers in cardiovascular medicine · 2025Pooled it
- Biomarker Profiling of Cardiac Causes for Chest Pain in Non-acute Coronary Syndrome Patients in West Virginia.Cureus · 2026Article
- Deep learning for cardiovascular disease: a comprehensive review of detection and risk forecasting.Frontiers in artificial intelligence · 2026Review
- Decoding coronary artery calcification: metabolic reprogramming features and a promising circulating biomarker PXDN.Frontiers in cell and developmental biology · 2026Article
- Assay-Dependent Variability in RBP4 and Adiponectin Quantification Affects Associations with Coronary Disease Severity and Doppler Echocardiographic Indices: A Comparative Study of Immunoturbidimetry and ELISA.International journal of general medicine · 2026Article
- Integrative blood profiling uncovers inflammatory network signatures in high-altitude pulmonary edema.Bioscience reports · 2025Article
- Association of Elevated Galectin-4 Concentrations with Obesity, Diabetes, and Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Chronic Copper Overload Triggers Inflammation in Mesenteric PVAT Alongside Changes in Renin-Angiotensin System-Related Pathways.Nutrients · 2025Article
- Beyond a Single Marker: An Update on the Comprehensive Evaluation of Right Ventricular Dysfunction in Pulmonary Thromboembolism.Life (Basel, Switzerland) · 2025Review
- Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions.Biomedicines · 2025Review
- H-FABP and Hs-cTnI Serum Concentrations Associate with the Development of Cardiovascular Events in Newly Diagnosed T2D, Pre-DM, and Normoglycemic Individuals.Vascular health and risk management · 2025Article
- Old, the new, more or less and the conundrum for biomarkers in cardiovascular diseases?World journal of clinical cases · 2024Article
- Unveiling TIMPs: A Systematic Review of Their Role as Biomarkers in Atherosclerosis and Coronary Artery Disease.Diseases (Basel, Switzerland) · 2024Review
- Association between augmented levels of the gut pro-hormone Proneurotensin and subclinical vascular damage.Scientific reports · 2024Article
- Exploring metabolically healthy obesity: prevalence, characteristics, and cardiovascular risk in the Iranian population based on the STEPS 2021.Journal of diabetes and metabolic disorders · 2024Article
- Dynamic Changes in Adiponectin and Resistin Drive Remission of Cardiometabolic Risk Biomarkers in Individuals with Obesity Following Bariatric Surgery.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- Cardiovascular biomarkers: exploring troponin and BNP applications in conditions related to carbon monoxide exposure.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the leading cause of death globally. Risk assessment is crucial for identifying at-risk individuals who require immediate attention as well as to guide the intensity of medical therapy to reduce subsequent risk of CVD. In the past decade, many risk prediction models have been proposed to estimate the risk of developing CVD. However, in patients with a history of CVD, the current models that based on traditional risk factors provide limited power in predicting recurrent cardiovascular events. Several biomarkers from different pathophysiological pathways have been identified to predict cardiovascular events, and the incorporation of biomarkers into risk assessment may contribute to enhance risk stratification in secondary prevention. This review focuses on biomarkers related to cardiovascular and metabolic diseases, including B-type natriuretic peptide, high-sensitivity cardiac troponin I, adiponectin, adipocyte fatty acid-binding protein, heart-type fatty acid-binding protein, lipocalin-2, fibroblast growth factor 19 and 21, retinol-binding protein 4, plasminogen activator inhibitor-1, 25-hydroxyvitamin D, and proprotein convertase subtilisin/kexin type 9, and discusses the potential utility of these biomarkers in cardiovascular risk prediction among patients with CVD. Many of these biomarkers have shown promise in improving risk prediction of CVD. Further research is needed to assess the validity of biomarker and whether the strategy for incorporating biomarker into clinical practice may help to optimize decision-making and therapeutic management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.